Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR183 | P32249 | 3/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.44 |
| ▸ | MAOB | P27338 | 9/20 | 0.38 |
| ▸ | P4HB | P07237 | 1/20 | 0.37 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | MAOA | P21397 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1950814 | 1.00 | GPR183 (0.50) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1953413 | 0.89 | GPR183 (0.48) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1953415 | 0.89 | GPR183 (0.48) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL14723846 | 0.86 | GPR183 (0.47) | GPR183MAPTL3MBTL1KDM4ENPC1 | |
| SCHEMBL1949275 | 0.83 | GPR183 (0.51) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1949277 | 0.83 | GPR183 (0.51) | GPR183NFKB1MAOBP4HBABCG2 | |
| SCHEMBL1952234 | 0.82 | GPR183 (0.46) | GPR183NFKB1MAOBMAPTL3MBTL1 | |
| SCHEMBL1952237 | 0.82 | GPR183 (0.46) | GPR183NFKB1MAOBMAPTL3MBTL1 | |
| SCHEMBL14723844 | 0.81 | GPR183 (0.47) | GPR183NFKB1MAOBMAPTL3MBTL1 | |
| SCHEMBL1952821 | 0.78 | RBP4 (0.46) | MAPTKDM4EMEN1LMNAKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| EP-2265588-B1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS INC (US) | 2013-06-26 | — | — | EP | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-8383629-B2 | Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 | VITAE PHARMACEUTICALS, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | VITAE PHARMACEUTICALS INC. | 2011-06-09 | — | — | US | disclosed |
| EP-2265588-A1 | INHIBITORS OF 11ß -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | Vitae Pharmaceuticals, Inc. (US) | 2010-12-29 | — | — | EP | disclosed |
| WO-2009108332-A1 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009108332-A1 | INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 | VITAE PHARMACEUTICALS, INC. (US) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136821-A1 | Inhibitors Of 11Beta-Hydroxysteroid Dehydrogenase Type 1 | HSD11B1, HSD17B1, HSD3B1 | GPR183 1523/4885NFKB1 1003/4885MAOB 511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.